Figure 2. Comparison of overall survival from initiation of first-line therapy in metastatic renal cell carcinoma (mRCC) patients treated in 2016-2020 (n=80) and those treated in 2008-2015 (n=133). Overall survival was significantly improved in the period of 2016-2020 compared with 2008-2015.